Revisión de las novedades presentadas en el XXVII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)

Fernández, Óscar; Cermeño, José Carlos Álvarez; González, Rocío López; Ruiz, Lluís Brieva; Hernández, Ma Carmen Calles; Estruch, Bonaventura Casanova; López, Manuel Comabella; Revilla, Virginia de las Heras; Merino, Juan Antonio García; Pérez, Miguel Ángel Hernández; Ayuso, Guillermo Izquierdo; Lallana, José Eustasio Meca; García, Delicias Muñoz; Urtaza, Javier Olascoaga; Guevara, Celia Oreja; González, José María Prieto; Torrentà, Lluís Ramió; Antigüedad, Alfredo Rodríguez; Romero-Pinel, Lucía; López, Fernando Sánchez; Lara, Nieves Téllez; Subirana, Ma del Mar Tintoré; Gairín, Xavier Montalbán; Post-ECTRIMS, Grupo Post-ECTRIMS Grupo

doi:10.33588/rn.5411.2012204

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of brain atrophy in an individual patient may be affected by a number of factors, including disease stage, MS phenotype, genetic factors, toxic agents and the presence of MS lesions. Patients with the apolipoprotein E-ε4 genotype showed an annual decrease in brain volume five times higher than in patients without this genotype [42], although other studies have reported that this genotype has no effect on brain atrophy [43]. Exposure to toxins such as cigarette smoke [44] has also been reported to be associated with increased brain atrophy rates.…”

Section: Brain Atrophy In Multiple Sclerosismentioning

confidence: 97%

Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis

Radü¹,

Bendfeldt²,

Mueller-Lenke³

et al. 2013

Swiss Med Wkly

View full text Add to dashboard Cite

Multiple sclerosis (MS) has traditionally been considered to be primarily an inflammatory demyelinating disorder. Nowadays it is recognised as both an inflammatory and a neurodegenerative condition. This recognition is reflected in the development of new disease-modifying therapies that may offer the potential to reduce axon damage, either by inhibiting neurodegeneration or by promoting endogenous repair mechanisms. Since there is only a limited correlation between the clinical features of MS and findings on conventional magnetic resonance imaging (MRI), for the evaluation of such therapies new outcome measures are warranted. Grey matter atrophy occurs in the earliest stages of MS, progresses faster than in healthy individuals, and shows significant correlations with MRI lesion load, cognitive function and measures of physical disability; indeed, brain atrophy is the best predictor of subsequent disability and can be readily measured using MRI. Furthermore, it is becoming clear that currently available therapies differ in their effects on brain atrophy, and this may have important implications for the management of MS. New MRI techniques and advances in software development offer an opportunity to extend brain atrophy measurements beyond research studies to the routine management of MS patients.

show abstract

Section: Brain Atrophy In Multiple Sclerosismentioning

confidence: 97%

Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis

Radü¹,

Bendfeldt²,

Mueller-Lenke³

et al. 2013

Swiss Med Wkly

View full text Add to dashboard Cite

show abstract

Nutrition Facts in Multiple Sclerosis

2015

View full text Add to dashboard Cite

The question whether dietary habits and lifestyle have influence on the course of multiple sclerosis (MS) is still a matter of debate, and at present, MS therapy is not associated with any information on diet and lifestyle. Here we show that dietary factors and lifestyle may exacerbate or ameliorate MS symptoms by modulating the inflammatory status of the disease both in relapsing-remitting MS and in primary-progressive MS. This is achieved by controlling both the metabolic and inflammatory pathways in the human cell and the composition of commensal gut microbiota. What increases inflammation are hypercaloric Western-style diets, characterized by high salt, animal fat, red meat, sugar-sweetened drinks, fried food, low fiber, and lack of physical exercise. The persistence of this type of diet upregulates the metabolism of human cells toward biosynthetic pathways including those of proinflammatory molecules and also leads to a dysbiotic gut microbiota, alteration of intestinal immunity, and low-grade systemic inflammation. Conversely, exercise and low-calorie diets based on the assumption of vegetables, fruit, legumes, fish, prebiotics, and probiotics act on nuclear receptors and enzymes that upregulate oxidative metabolism, downregulate the synthesis of proinflammatory molecules, and restore or maintain a healthy symbiotic gut microbiota. Now that we know the molecular mechanisms by which dietary factors and exercise affect the inflammatory status in MS, we can expect that a nutritional intervention with anti-inflammatory food and dietary supplements can alleviate possible side effects of immune-modulatory drugs and the symptoms of chronic fatigue syndrome and thus favor patient wellness.

show abstract

Revisión de las novedades presentadas en el XXVII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)

Cited by 2 publications

References 0 publications

Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis

Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis

Nutrition Facts in Multiple Sclerosis

Contact Info

Product

Resources

About